Sen. Tommy Tuberville Sells Off Shares of Amgen Inc. (NASDAQ:AMGN)

Senator Tommy Tuberville (R-Alabama) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on May 15th, the Senator disclosed that they had sold between $15,001 and $50,000 in Amgen stock on April 15th.

Senator Tommy Tuberville also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Duke Energy (NYSE:DUK) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of CSX (NASDAQ:CSX) on 4/15/2025.
• Sold $1,001 – $15,000 in shares of Bristol-Myers Squibb (NYSE:BMY) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of PayPal (NASDAQ:PYPL) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of Constellation Brands (NYSE:STZ) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of Alphabet (NASDAQ:GOOGL) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of The Goldman Sachs Group (NYSE:GS) on 4/15/2025.
• Purchased $50,001 – $100,000 in shares of iShares Broad USD Investment Grade Corporate Bond ETF (NASDAQ:USIG) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 4/15/2025.
• Sold $15,001 – $50,000 in shares of Mastercard (NYSE:MA) on 4/15/2025.

Amgen Price Performance

NASDAQ AMGN opened at $272.41 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a market capitalization of $146.48 billion, a PE ratio of 36.08, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The firm’s 50 day moving average is $291.00 and its 200-day moving average is $288.09.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The company had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. During the same period last year, the company earned $3.96 earnings per share. The firm’s revenue was up 9.4% compared to the same quarter last year. Equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.49%. Amgen’s dividend payout ratio (DPR) is presently 86.86%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on AMGN. Mizuho lifted their price objective on shares of Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a report on Wednesday, May 7th. Citigroup restated a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Piper Sandler lowered their target price on shares of Amgen from $329.00 to $328.00 and set an “overweight” rating on the stock in a report on Friday. Bank of America boosted their target price on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a report on Wednesday, March 5th. Finally, Wells Fargo & Company restated an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $310.18.

Hedge Funds Weigh In On Amgen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Centricity Wealth Management LLC bought a new stake in shares of Amgen in the fourth quarter valued at about $25,000. Wealth Preservation Advisors LLC bought a new stake in shares of Amgen in the first quarter valued at about $25,000. Pinney & Scofield Inc. bought a new stake in shares of Amgen in the fourth quarter valued at about $26,000. First Pacific Financial boosted its position in shares of Amgen by 304.5% in the first quarter. First Pacific Financial now owns 89 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 67 shares during the period. Finally, Ritter Daniher Financial Advisory LLC DE boosted its position in shares of Amgen by 66.2% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 51 shares during the period. 76.50% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP David M. Reese sold 8,711 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total value of $2,554,239.42. Following the completion of the sale, the executive vice president now owns 62,147 shares of the company’s stock, valued at approximately $18,222,743.34. The trade was a 12.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.76% of the stock is currently owned by company insiders.

About Senator Tuberville

Tommy Tuberville (Republican Party) (also known as Coach) is a member of the U.S. Senate from Alabama. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Tuberville (Republican Party) ran for election to the U.S. Senate to represent Alabama. He won in the general election on November 3, 2020. Tuberville was head coach for several college football teams between 1995 and 2016, including at Auburn University and the University of Cincinnati. Tommy Tuberville was born in Camden, Arkansas, and lives in Auburn, Alabama. Tuberville’s career experience includes working as a studio analyst with ESPN and as the head football coach of the University of Mississippi, the University of Auburn, Texas Tech University, and the University of Cincinnati.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.